Guillermo QuindÃ³s AndrÃ©s

List of Publications by Year
in descending order

159 papers	5,077 citations	71097 41 h-index	133244 59 g-index
201 all docs	201 docs citations	201 times ranked	4805 citing authors

#	Article	IF	Citations
1	Epidemiology of candidaemia and invasive candidiasis. A changing face. Revista Iberoamericana De Micologia, 2014, 31, 42-48.	0.9	153
2	Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. Journal of Antimicrobial Chemotherapy, 2012, 67, 1181-1187.	3.0	136
3	Prospective Multicenter Study of the Epidemiology, Molecular Identification, and Antifungal Susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Isolated from Patients with Candidemia. Antimicrobial Agents and Chemotherapy, 2011, 55, 5590-5596.	3.2	126
4	Graphene Oxideâ€“Silver Nanoparticle Nanohybrids: Synthesis, Characterization, and Antimicrobial Properties. Nanomaterials, 2020, 10, 376.	4.1	123
5	Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagnostic Microbiology and Infectious Disease, 2003, 45, 203-206.	1.8	117
6	Fungal co-infection in COVID-19 patients: Should we be concerned?. Revista Iberoamericana De Micologia, 2020, 37, 41-46.	0.9	113
7	Candida dubliniensis, a new fungal pathogen. Journal of Basic Microbiology, 2002, 42, 207.	3.3	96
8	Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. Journal of Antimicrobial Chemotherapy, 2003, 53, 74-80.	3.0	93
9	In vitro activities of natural products against oral Candida isolates from denture wearers. BMC Complementary and Alternative Medicine, 2011, 11, 119.	3.7	90
10	Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?. International Journal of Nanomedicine, 2016, Volume 11, 3715-3730.	6.7	85
11	The continuous changes in the aetiology and epidemiology of invasive candidiasis: from familiar Candida albicans to multiresistant Candida auris. International Microbiology, 2018, 21, 107-119.	2.4	81
12	In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. Journal of Antimicrobial Chemotherapy, 1999, 44, 397-401.	3.0	76
13	Enteric Fever-Like Syndrome Caused by Raoultella ornithinolytica (Klebsiella) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	3.9	75
14	Biofilm development by clinical isolates ofMalassezia pachydermatis. Medical Mycology, 2007, 45, 357-361.	0.7	73
15	Synthesis, Physical, Mechanical and Antibacterial Properties of Nanocomposites Based on Poly(vinyl) Tj ETQq1 1 0.784314 rgBT /Over	4.5	73
16	Isolation of Candida dubliniensis in denture stomatitis. Archives of Oral Biology, 2009, 54, 127-131.	1.8	72
17	Effect of biomaterials hydrophobicity and roughness on biofilm development. Journal of Materials Science: Materials in Medicine, 2019, 30, 77.	3.6	70
18	Utilidad de la detecciÃ³n de (1â†'3)-ÃŸ-D-glucano y anticuerpos anti-micelio de Candida albicans para el diagnÃ³stico y seguimiento terapÃ©utico de la candidiasis invasora en pacientes neutropÃ©nicos adultos. Revista Iberoamericana De Micologia, 2006, 23, 209-215.	0.9	69

#	Article	IF	Citations
19	Therapeutic tools for oral candidiasis: Current and new antifungal drugs. Medicina Oral, Patologia Oral Y Cirugia Bucal, 2019, 24, 0-0.	1.7	69
20	Role of Porphyromonas gingivalis in oral squamous cell carcinoma development: A systematic review. Journal of Periodontal Research, 2020, 55, 13-22.	2.7	69
21	Biotype Diversity of Candida parapsilosis and Its Relationship to the Clinical Source and Experimental Pathogenicity. Journal of Infectious Diseases, 1995, 171, 967-975.	4.0	68
22	Evaluation of the New Chromogenic Medium Candida ID 2 for Isolation and Identification of Candida albicans and Other Medically Important Candida Species. Journal of Clinical Microbiology, 2006, 44, 3340-3345.	3.9	62
23	Prevalencia, microbiologÃa y patrones de sensibilidad a los antifÃºngicos de los aislamientos orales de Candida que colonizaban o infectaban a pacientes mexicanos con infecciÃ³n por VIH o sida y a personas sanas. Revista Iberoamericana De Micologia, 2005, 22, 83-92.	0.9	60
24	Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital. Journal of Antimicrobial Chemotherapy, 2011, 66, 2315-2322.	3.0	59
25	Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in Candida and Aspergillus Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	59
26	In vitro Susceptibility of Candida dubliniensis to Current and New Antifungal Agents. Chemotherapy, 2000, 46, 395-401.	1.6	58
27	Oral Candida Isolates Colonizing or Infecting Human Immunodeficiency Virus-Infected and Healthy Persons in Mexico. Journal of Clinical Microbiology, 2005, 43, 4159-4162.	3.9	58
28	Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method. Antimicrobial Agents and Chemotherapy, 2015, 59, 6725-6732.	3.2	57
29	Fungicidal Monoclonal Antibody C7 Interferes with Iron Acquisition in Candida albicans. Antimicrobial Agents and Chemotherapy, 2011, 55, 3156-3163.	3.2	55
30	In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. Journal of Antimicrobial Chemotherapy, 1999, 44, 697-700.	3.0	54
31	Value of detection of antibodies toCandida albicans germ tube in the diagnosis of systemic candidosis. European Journal of Clinical Microbiology and Infectious Diseases, 1990, 9, 178-183.	2.9	53
32	Phytochemical composition, anti-biofilm and anti-quorum sensing potential of fruit, stem and leaves of Salvadora persica L. methanolic extracts. Microbial Pathogenesis, 2017, 109, 169-176.	2.9	53
33	Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. Journal of Antimicrobial Chemotherapy, 2003, 51, 163-166.	3.0	51
34	Effect of salivary secretory IgA on the adhesion of Candida albicans to polystyrene. Microbiology (United Kingdom), 2000, 146, 2105-2112.	1.8	49
35	One-step eco-friendly synthesized silver-graphene oxide/poly(vinyl alcohol) antibacterial nanocomposites. Carbon, 2019, 150, 101-116.	10.3	49
36	Use of DNA fingerprinting and biotyping methods to study a Candida albicans outbreak in a neonatal intensive care unit. Pediatric Infectious Disease Journal, 1994, 13, 899-905.	2.0	47

#	Article	IF	Citations
37	In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis. International Journal of Antimicrobial Agents, 2007, 30, 157-161.	2.5	47
38	Detection of antibodies toCandida albicans germ tube in the diagnosis of systemic candidiasis. European Journal of Clinical Microbiology and Infectious Diseases, 1987, 6, 142-146.	2.9	46
39	Prevalence and antifungal susceptibility profiles of Candida glabrata, Candida parapsilosis and their close-related species in oral candidiasis. Archives of Oral Biology, 2018, 95, 100-107.	1.8	44
40	Evaluation of a commercial medium for identification ofCandida species. European Journal of Clinical Microbiology and Infectious Diseases, 1996, 15, 153-158.	2.9	43
41	Fatal Disseminated Infection by Scedosporium inflatum after Bone Marrow Transplantation. Scandinavian Journal of Infectious Diseases, 1993, 25, 389-393.	1.5	41
42	Clinical factors associated with a Candida albicansGerm Tube Antibody positive test in Intensive Care Unit patients. BMC Infectious Diseases, 2011, 11, 60.	2.9	41
43	Supplementation of CHROMagar Candida Medium with Pal's Medium for Rapid Identification of Candida dubliniensis. Journal of Clinical Microbiology, 2005, 43, 5768-5770.	3.9	38
44	Isolation ofCandida africana, probable atypical strains ofCandida albicans, from a patient with vaginitis. Medical Mycology, 2008, 46, 167-170.	0.7	37
45	Oral Candida colonization in patients with chronic periodontitis. Is there any relationship?. Revista Iberoamericana De Micologia, 2018, 35, 134-139.	0.9	37
46	Sertaconazole: updated review of a topical antifungal agent. Expert Review of Anti-Infective Therapy, 2005, 3, 333-342.	4.4	36
47	Evaluation of the Albicans IDR plate method for the rapid identification of Candida albicans. Mycoses, 2009, 36, 417-420.	4.0	36
48	Clinical significance of the detection of Candida albicans germ tube-specific antibodies in critically ill patients. Clinical Microbiology and Infection, 2009, 15, 592-595.	6.0	36
49	Comparative evaluation of three commercial software packages for analysis of DNA polymorphism patterns. Clinical Microbiology and Infection, 2001, 7, 331-336.	6.0	34
50	Evaluation of Bichro-Dubli FumouzeÂ® to distinguish Candida dubliniensis from Candida albicans. Diagnostic Microbiology and Infectious Disease, 2006, 55, 165-167.	1.8	34
51	Comparative in vitro Antifungal Activity of Amphotericin B Lipid Complex, Amphotericin B and Fluconazole. Chemotherapy, 2000, 46, 235-244.	1.6	33
52	Phospholipase and proteinase activities of Candida isolates from denture wearers. Mycoses, 2011, 54, e10-e16.	4.0	33
53	In vitro antifungal susceptibility testing of filamentous fungi with Sensititre Yeast OneTM. Mycoses, 2006, 49, 293-297.	4.0	32
54	Disinfectant Activity of A Portable Ultraviolet C Equipment. International Journal of Environmental Research and Public Health, 2019, 16, 4747.	2.6	30

#	Article	IF	Citations
55	Is there a role for antibody testing in the diagnosis of invasive candidiasis?. Revista Iberoamericana De Micologia, 2004, 21, 10-4.	0.9	30
56	In VitroFungicidal Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis Evaluated by Time-Kill Studies. Antimicrobial Agents and Chemotherapy, 2015, 59, 3615-3618.	3.2	29
57	In vitro susceptibility ofAeromonas caviae, Aeromonas hydrophila andAeromonas sobria to fifteen antibacterial agents. European Journal of Clinical Microbiology and Infectious Diseases, 1990, 9, 413-417.	2.9	28
58	Detection of Anti-CandidaalbcansIgE Antibodies in Vaginal Washes from Patients with Acute Vulvovaginal Candidiasis. Gynecologic and Obstetric Investigation, 1994, 37, 110-114.	1.6	28
59	Multicenter Evaluation of ATB Fungus: A Standardized Micromethod for Yeast Susceptibility Testing. Chemotherapy, 1994, 40, 245-251.	1.6	28
60	Candida biotypes in patients with oral leukoplakia and lichen planus. Mycopathologia, 1996, 134, 75-82.	3.1	28
61	Accurate Identification of Candida parapsilosis (Sensu Lato) by Use of Mitochondrial DNA and Real-Time PCR. Journal of Clinical Microbiology, 2012, 50, 2310-2314.	3.9	28
62	In vitro Antifungal Activity of Sertaconazole Compared with Nine Other Drugs against 250 Clinical Isolates of Dermatophytes and Scopulariopsis brevicaulis. Chemotherapy, 2004, 50, 308-313.	1.6	27
63	Evaluation of CHROM-Pal medium for the isolation and direct identification of Candida dubliniensis in primary cultures from the oral cavity. Journal of Medical Microbiology, 2009, 58, 1437-1442.	1.8	27
64	Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis. Expert Review of Anti-Infective Therapy, 2013, 11, 347-358.	4.4	27
65	Developing collaborative works for faster progress on fungal respiratory infections in cystic fibrosis. Medical Mycology, 2018, 56, S42-S59.	0.7	27
66	Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. Journal of Antimicrobial Chemotherapy, 2005, 55, 317-319.	3.0	26
67	Kinetic Patterns of Candida albicans Germ Tube Antibody in Critically Ill Patients: Influence on Mortality. Vaccine Journal, 2009, 16, 1527-1528.	3.1	26
68	Evaluation of API ID 32CÂ® and VITEK-2Â® to identify Candida dubliniensis. Diagnostic Microbiology and Infectious Disease, 2004, 50, 219-221.	1.8	25
69	Virulence ofCandida aurisfrom different clinical origins inCaenorhabditis elegansandGalleria mellonellahost models. Virulence, 2021, 12, 1063-1075.	4.4	25
70	New microbiological techniques for the diagnosis of invasive mycoses caused by filamentous fungi. Clinical Microbiology and Infection, 2006, 12, 40-52.	6.0	24
71	Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis. International Journal of Antimicrobial Agents, 2008, 31, 540-543.	2.5	24
72	Usefulness of the Non-conventional Caenorhabditis elegans Model to Assess Candida Virulence. Mycopathologia, 2017, 182, 785-795.	3.1	24

#	Article	IF	Citations
73	In vitro activities of carvacrol, cinnamaldehyde and thymol against Candida biofilms. Biomedicine and Pharmacotherapy, 2021, 143, 112218.	5.6	24
74	In-vitro activity of 5-fluorocytosine against 1,021 Spanish clinical isolates of Candida and other medically important yeasts. Revista Iberoamericana De Micologia, 2004, 21, 63-9.	0.9	24
75	Candidaantigens and immune responses: implications for a vaccine. Expert Review of Vaccines, 2014, 13, 1001-1012.	4.4	23
76	A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp.. Journal of Antimicrobial Chemotherapy, 1999, 43, 477-481.	3.0	22
77	In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris. Antibiotics, 2021, 10, 355.	3.7	22
78	Usefulness of Candida ID2 agar for the presumptive identification ofCandida dubliniensis. Medical Mycology, 2006, 44, 611-615.	0.7	21
79	Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre. International Journal of Antimicrobial Agents, 2008, 31, 266-271.	2.5	21
80	Reactivity of Candida albicans Germ Tubes with Salivary Secretory IgA. Journal of Dental Research, 1996, 75, 1979-1985.	5.2	20
81	In Vitro Activities of New Triazole Antifungal Agents, Posaconazole and Voriconazole, Against Oral Candida Isolates from Patients Suffering from Denture Stomatitis. Mycopathologia, 2012, 173, 35-46.	3.1	20
82	Paradoxical Growth of Candida dubliniensis Does Not Preclude In Vivo Response to Echinocandin Therapy. Antimicrobial Agents and Chemotherapy, 2009, 53, 5297-5299.	3.2	18
83	Comparison of the in vitro activity of echinocandins against Candida albicans , Candida dubliniensis , and Candida africana by timeâ€“kill curves. Diagnostic Microbiology and Infectious Disease, 2015, 82, 57-61.	1.8	18
84	Candida albicans biofilms on different materials for manufacturing implant abutments and prostheses. Medicina Oral, Patologia Oral Y Cirugia Bucal, 2020, 25, e13-e20.	1.7	18
85	Influence of Environmental pH on the Reactivity of Candida albicans with Salivary IgA. Journal of Dental Research, 2000, 79, 1439-1442.	5.2	17
86	EvaluaciÃ³n comparativa de ATB Fungus 2 y Sensititre YeastOne en el estudio de la sensibilidad in vitro de Candida a los antifÃºngicos. Revista Iberoamericana De Micologia, 2008, 25, 3-6.	0.9	17
87	Periodontopathogen and Epsteinâ€Barr Virus Contamination Affects Transplanted Bone Volume in Sinus Augmentation. Journal of Periodontology, 2012, 83, 162-173.	3.4	17
88	Caries and Candida colonisation in adult patients in Basque Country (Spain). Mycoses, 2016, 59, 234-240.	4.0	17
89	ComparaciÃ³n de un mÃ©todo de amplificaciÃ³n aleatoria del ADN polimorfo (RAPD) y el sistema ATB ID32C para la identificaciÃ³n de aislamientos clÃnicos de Candida. Revista Iberoamericana De Micologia, 2007, 24, 148-151.	0.9	16
90	Antifungal Activity of the Human Uterine Cervical Stem Cells Conditioned Medium (hUCESC-CM) Against Candida albicans and Other Medically Relevant Species of Candida. Frontiers in Microbiology, 2018, 9, 2818.	3.5	16

#	Article	IF	Citations
91	In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, .	3.9	15
92	Ciclopiroxolamine: in vitro antifungal activity against clinical yeast isolates. International Journal of Antimicrobial Agents, 2002, 20, 375-379.	2.5	14
93	Current Developments in Anti-Fungal Agents. Anti-Infective Agents in Medicinal Chemistry, 2004, 3, 297-323.	0.9	14
94	Differences in extracellular enzymatic activity between Candida dubliniensis and Candida albicans isolates. Revista Iberoamericana De Micologia, 2004, 21, 70-4.	0.9	14
95	In Vitro Interactions of Micafungin with Amphotericin B against Clinical Isolates of Candida spp. Antimicrobial Agents and Chemotherapy, 2008, 52, 1529-1532.	3.2	13
96	Evaluation of the VITEK 2 system to test the susceptibility ofCandidaspp.,Trichosporon asahiiandCryptococcus neoformansto amphotericin B, flucytosine, fluconazole and voriconazole: a comparison with the M27-A3 reference method. Medical Mycology, 2010, 48, 710-719.	0.7	13
97	EPICO 2.0 project. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations. Revista Iberoamericana De Micologia, 2014, 31, 157-175.	0.9	13
98	Candidal infection of bone: Assessment of serologic tests in diagnosis and management. Diagnostic Microbiology and Infectious Disease, 1990, 13, 297-302.	1.8	12
99	Ã‰pico project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients. Revista Iberoamericana De Micologia, 2013, 30, 135-149.	0.9	12
100	In Vitro Antifungal Susceptibility of Oral Candida Isolates from Patients Suffering from Caries and Chronic Periodontitis. Mycopathologia, 2017, 182, 471-485.	3.1	12
101	In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against Candida auris. Pharmaceutics, 2021, 13, 1333.	4.5	12
102	Cytological changes in oral mucosa in denture stomatitis. Gerodontology, 1996, 13, 63-67.	2.0	11
103	In Vitro Activity of a New Liposomal Nystatin Formulation Against Opportunistic Fungal Pathogens. European Journal of Clinical Microbiology and Infectious Diseases, 2000, 19, 645-648.	2.9	11
104	In vitro activity of micafungin combined with itraconazole against Candida spp.. International Journal of Antimicrobial Agents, 2007, 30, 463-465.	2.5	11
105	In VitroAntifungal Activity of Sertaconazole Nitrate Against Recent Isolates of Onychomycosis Causative Agents. Journal of Chemotherapy, 2008, 20, 521-523.	1.5	11
106	Variation in biofilm formation among blood and oral isolates of Candida albicans and Candida dubliniensis. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2011, 29, 660-665.	0.5	11
107	Postantifungal effect of caspofungin against the Candida albicans and Candida parapsilosis clades. Diagnostic Microbiology and Infectious Disease, 2016, 86, 172-177.	1.8	11
108	Detection and characterization of surface microbial contamination in emergency ambulances. American Journal of Infection Control, 2017, 45, 69-71.	2.3	11

#	Article	IF	Citations
109	Caenorhabditis elegans as a Model System To Assess Candida glabrata, Candida nivariensis , and Candida bracarensis Virulence and Antifungal Efficacy. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	11
110	Utility of albicans ID plate for rapid identification of Candida albicans in clinical samples. Mycopathologia, 1996, 136, 17-20.	3.1	10
111	Serological Differentiation of Experimentally Induced Candida dubliniensis and Candida albicans Infections. Journal of Clinical Microbiology, 2001, 39, 2999-3001.	3.9	10
112	Performance of BacticardTM Candida compared with the germ tube test for the presumptive identification of Candida albicans. Mycoses, 2003, 46, 467-470.	4.0	10
113	Activity of Caspofungin and Voriconazole against Clinical Isolates of <i>Candida </i>and Other Medically Important Yeasts by the CLSI M-44A Disk Diffusion Method with Neo-Sensitabs Tablets. Chemotherapy, 2008, 54, 38-42.	1.6	10
114	Development and Characterization of Monoolein-Based Liposomes of Carvacrol, Cinnamaldehyde, Citral, or Thymol with Anti- Candida Activities. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	10
115	Identification of antigens reacting with anti-Candida albicans germ tube antibodies. European Journal of Epidemiology, 1992, 8, 356-361.	5.7	9
116	In vitro interaction of micafungin and fluconazole against Candida. Journal of Antimicrobial Chemotherapy, 2007, 60, 188-190.	3.0	9
117	Saccharomyces cerevisiae Vaginitis: Microbiology and In Vitro Antifungal Susceptibility. Mycopathologia, 2011, 172, 201-205.	3.1	9
118	Postantifungal Effect of Micafungin against the Species Complexes of Candida albicans and Candida parapsilosis. PLoS ONE, 2015, 10, e0132730.	2.5	9
119	Twitter as a Tool for Teaching and Communicating Microbiology: The #microMOOCSEM Initiative. Journal of Microbiology and Biology Education, 2016, 17, 492-494.	1.0	9
120	Candida parapsilosis Colony Morphotype Forecasts Biofilm Formation of Clinical Isolates. Journal of Fungi (Basel, Switzerland), 2021, 7, 33.	3.5	9
121	Comparison of in vitro Antifungal Activities of Amphotericin B Lipid Complex with Itraconazole against 708 Clinical Yeast Isolates and Opportunistic Moulds Determined by National Committee for Clinical Laboratory Standards Methods M27-A and M38-P. Chemotherapy, 2002, 48, 224-231.	1.6	8
122	Vulvovaginal candidiasis refractory to treatment with fluconazole. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1992, 44, 77-80.	1.1	7
123	Sertaconazole:In-VitroAntifungal Activity Against Vaginal and Other Superficial Yeast Isolates. Journal of Chemotherapy, 2001, 13, 555-562.	1.5	7
124	Comparison of the Sensititre YeastOne Colorimetric Microdilution Panel and the NCCLS Broth Microdilution Method for Antifungal Susceptibility Testing against Candida Species. Chemotherapy, 2002, 48, 21-25.	1.6	7
125	In VitroActivities of Voriconazole and Five Licensed Antifungal Agents AgainstCandida dubliniensis:Comparison of CLSI M27-A2, Sensititre YeastOne, Disk Diffusion, and Etest Methods. Microbial Drug Resistance, 2006, 12, 246-251.	2.0	7
126	Vancomycin heteroresistant community associated methicillin-resistant Staphylococcus aureus ST72-SCCmecIVa strain colonizing the nostrils of a five-year-old Spanish girl. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 148-152.	0.5	7

#	Article	IF	Citations
127	Killing kinetics of anidulafungin, caspofungin and micafungin against Candida parapsilosis species complex: Evaluation of the fungicidal activity. Revista Iberoamericana De Micologia, 2019, 36, 24-29.	0.9	7
128	Candida duobushaemulonii: An Old But Unreported Pathogen. Journal of Fungi (Basel, Switzerland), 2020, 6, 374.	3.5	7
129	Comparison of Tablet and Disk Diffusion Methods for Fluconazole and VoriconazoleIn VitroActivity Testing Against Clinical Yeast Isolates. Journal of Chemotherapy, 2007, 19, 172-177.	1.5	6
130	In vitroactivity of voriconazole against Mexican oral yeast isolates. Mycoses, 2010, 53, 200-203.	4.0	6
131	Anidulafungin in Treatment of Experimental Invasive Infection by Candida parapsilosis: In Vitro Activity, (1â†'3)-Î²- <scp>d</scp> -Glucan and Mannan Serum Levels, Histopathological Findings, and In Vivo Efficacy. Antimicrobial Agents and Chemotherapy, 2011, 55, 4985-4989.	3.2	6
132	In vitro pharmacodynamic modelling of anidulafungin against Candida spp.. International Journal of Antimicrobial Agents, 2016, 47, 178-183.	2.5	6
133	Design and validation of a multiplex PCR protocol for microsatellite typing of Candida parapsilosis sensu stricto isolates. BMC Genomics, 2018, 19, 718.	2.8	6
134	Cellular and humoral immune responses to Candida albicans in subcutaneously infected mice. Mycopathologia, 1985, 92, 11-18.	3.1	5
135	Isolation of dysgonic strains ofMicrosporum canisin Bilbao (Spain). Medical Mycology, 1989, 27, 391-395.	0.7	5
136	Different Antibody Response againstCandidaalbicansCell Wall Antigens in Cervicovaginal Secretions of Patients with Vulvovaginal Candidiasis. Gynecologic and Obstetric Investigation, 1990, 30, 174-177.	1.6	5
137	Validation of the PCRâ€“dHPLC method for rapid identification of Candida glabrata phylogenetically related species in different biological matrices. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 893-894, 150-156.	2.3	5
138	EPICO 4.0. â€˜Total qualityâ€™ in the management of invasive candidiasis in critically ill patients by analysing the integrated process. Revista Iberoamericana De Micologia, 2017, 34, 143-157.	0.9	5
139	In Vitro Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Amphotericin B against Candida auris. Pharmaceutics, 2021, 13, 1767.	4.5	5
140	In vitro and in vivo anti-Candida activity of citral in combination with fluconazole. Journal of Oral Microbiology, 2022, 14, 2045813.	2.7	5
141	A new method of antibiotyping yeasts for subspecies discrimination and distribution in human clinical specimens. European Journal of Epidemiology, 1996, 12, 55-62.	5.7	3
142	Aislamiento de Issatchenkia occidentalis en el esÃ³fago de un paciente con leucemia. Revista Iberoamericana De Micologia, 2006, 23, 235-237.	0.9	3
143	Utility of two PCRâ€RFLPâ€based techniques for identification of Candida parapsilosis complex blood isolates. Mycoses, 2020, 63, 461-470.	4.0	3
144	Postantifungal effect of anidulafungin against Candida albicans, Candida dubliniensis, Candida africana, Candida parapsilosis, Candida metapsilosis and Candida orthopsilosis. Revista Espanola De Quimioterapia, 2019, 32, 183-188.	1.3	3

#	Article	IF	Citations
145	Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?. Journal of Fungi (Basel, Switzerland), 2022, 8, 727.	3.5	3
146	Ã‰pico project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients. Revista EspaÃ±ola De AnestesiologÃa Y ReanimaciÃ³n, 2013, 60, e1-e18.	0.3	2
147	Vancomycin heteroresistant community associated methicillin-resistant Staphylococcus aureus ST72-SCCmecIVa strain colonizing the nostrils of a five-year-old Spanish girl. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 148-152.	0.3	2
148	Candidiasis by Candida glabrata, Candida nivariensis and Candida bracarensis in Galleria mellonella: Virulence and Therapeutic Responses to Echinocandins. Journal of Fungi (Basel, Switzerland), 2021, 7, 998.	3.5	2
149	Determination of monosaccharides by high-performance liquid chromatography in systemic candidosis. Biomedical Applications, 1990, 525, 169-175.	1.7	1
150	Latest developments in fungal lung infection in solid organ transplantation (SOT). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2008, 26, 49-57.	0.5	1
151	State of the Art in the Laboratory Methods for the Diagnosis of Invasive Fungal Diseases. , 2014, , 281-297.		1
152	EPICO 3.0. Management of non-neutropenic patients in medical wards. Revista Iberoamericana De Micologia, 2016, 33, 216-223.	0.9	1
153	Impact of a multifaceted educational intervention including serious games to improve the management of invasive candidiasis in critically ill patients. Medicina Intensiva, 2017, 41, 3-11.	0.7	1
154	Update on invasive fungal infections: the last two years. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2007, 25, 19-27.	0.5	0
155	Posaconazole susceptibility of clinical yeast isolates determined by an agar diffusion and microdilution method. International Journal of Antimicrobial Agents, 2011, 37, 271-273.	2.5	0
156	Editorial: EHUDW01, First EHU-DELFIN Program Workshop, Bilbao, Jul, 201. , 0, , .		0
157	Comparative Study of Invasive Candidiasis in Mexico and Spain. , 0, , .		0
158	Study of microbiological laboratory techniques for the etiological diagnosis and guidance in the treatment of invasive candidiasis. , 0, , .		0
159	Galleria mellonella insektua eta Caenorhabditis elegans nematodoa, infekzio eredu boteretsuak Candida glabrata eta erlazionatutako espezieen birulentzia ikertzeko. Ekaia (journal), 2020, , 175-190.	0.0	0